The subthalamic nucleus (STN) is one of the most severely affected brain structures in Progressive Supranuclear Palsy (PSP), harboring dense globose neurofibrillary tangles composed of hyperphosphorylated 4R tau[1]. STN degeneration is a pathological hallmark of PSP and directly contributes to the postural instability, falls, and akinesia that define the disease. The STN occupies a critical position in basal ganglia circuitry as the primary excitatory nucleus driving the indirect and hyperdirect pathways, making its degeneration uniquely devastating for motor control[2].
The STN is a small, biconvex nucleus situated ventral to the zona incerta and dorsolateral to the substantia nigra in the posterior diencephalon[3]. Despite its small size (approximately 240 mm³), the STN contains approximately 560,000 glutamatergic projection neurons densely packed within three functional territories:
The STN is the only glutamatergic (excitatory) nucleus in the basal ganglia, functioning as a critical brake on unwanted movements[4]:
STN degeneration in PSP follows a characteristic pattern[1:1][6]:
The cryo-EM structure of PSP tau filaments reveals a distinct C-shaped fold that differs from both Alzheimer's disease and CBD tau conformations, supporting the "tau strain" hypothesis[7].
STN neuronal loss disrupts both the indirect and hyperdirect pathways:
Classic PSP shows the most severe STN pathology[1:2]:
PSP-P shows relatively milder STN involvement:
STN pathology in PSP-PAGF shows selective pattern:
Several factors contribute to the STN's preferential vulnerability in PSP[11]:
The STN's extensive connectivity makes it a critical node for tau spreading:
Current pharmacological options for STN-related symptoms are limited[15]:
Unlike in Parkinson's disease, STN DBS has limited utility in PSP[16]:
Tau-targeted therapies aim to halt STN degeneration:
In Corticobasal Syndrome (CBS), STN degeneration is typically less severe than in Richardson syndrome but still contributes to the akinetic-rigid phenotype. CBD pathology shows prominent astrocytic plaques in the STN neuropil rather than the globose NFTs characteristic of PSP. The severity of STN tau burden, assessed by tau PET or post-mortem neuropathology, helps differentiate PSP-RS (most severe) from PSP-P and CBS (less severe subcortical involvement)[1:3][6:1]. Combined STN and cortical pathology scoring may improve antemortem diagnostic accuracy for distinguishing these overlapping 4R tauopathies.
Progressive Supranuclear Palsy — Disease overview
Globus Pallidus Neurons in PSP
Substantia Nigra Neurons in PSP
4R Tauopathy Mechanisms
Basal Ganglia
CBS/PSP Genetic Architecture
Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome. Neurology. 1994. ↩︎ ↩︎ ↩︎ ↩︎
Parent A, Hazrati LN. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev. 1995. ↩︎
Yelnik J, Percheron G. Subthalamic neurons in primates: a quantitative and comparative analysis. Neuroscience. 1979. ↩︎
Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res. 2002. ↩︎
Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 2007. ↩︎ ↩︎
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010. ↩︎ ↩︎
Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021. ↩︎
Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain. 2005. ↩︎
Welter ML, Do MC, Chastan N, et al. Control of vertical components of gait during initiation of walking in normal adults and patients with progressive supranuclear palsy. Gait Posture. 2007. ↩︎
Hardman CD, Halliday GM, McRitchie DA, et al. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol. 1997. ↩︎
Kaat LD, Boon AJW, Kamphorst W, Ravid R, Dubelaar EJG, van Swieten JC. Frontal presentation in progressive supranuclear palsy. Neurology. 2007. ↩︎
Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007. ↩︎
Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci. 2003. ↩︎
Whitwell JL, Lowe VJ, Tosakulwong N, et al. 18F Flortaucipir tau-PET in progressive supranuclear palsy. Mov Disord. 2017. ↩︎
Respondek G, Stamelou M, Höglinger GU. Current and future therapeutic approaches to PSP. Expert Rev Neurother. 2019. ↩︎
Brusa L, Iani C, Ceravolo R, et al. Implantation of the subthalamic nucleus in a patient with progressive supranuclear palsy. J Neural Transm. 2005. ↩︎